Peter Fedichev

Peter Fedichev is a physicist and biotechnologist. He worked on ultracold quantum systems before moving into computational drug design and later longevity research.

Peter Fedichev
Born	Peter Olegovich Fedichev
Alma mater	Moscow Institute of Physics and Technology (M.S.); University of Amsterdam (Ph.D.)
Occupations	Physicist, biotechnologist, entrepreneur
Known for	Research on quantitative models of ageing; co-founding Gero.ai

He is the co-founder and chief executive officer of Gero.ai, a biotechnology company based in Singapore that applies physics-based and machine-learning methods to ageing and disease research.

Education and early career

Fedichev received an M.Sc. in theoretical physics from the Moscow Institute of Physics and Technology while conducting research at the Kurchatov Institute. In 1994 he joined the University of Amsterdam and the AMOLF institute, completing a Ph.D. cum laude in theoretical physics. He later worked at the University of Innsbruck on condensed-matter and quantum-gas systems.

Research

During the 2000s Fedichev co-founded Quantum Pharmaceuticals, an early company exploring computational drug design. Since 2015 he has led Gero.ai, whose studies use large health datasets and mathematical models to analyse ageing dynamics. In a 2021 study published in Nature Communications, Fedichev and co‑authors analysed longitudinal blood biomarker data and step‑count records to propose that human resilience declines with age and may limit maximum lifespan. Scientific American cited him noting that the convergence of blood and activity data suggests a “real pace-of-aging factor”.

Fedichev has written on the use of physical and mathematical approaches to describe biological ageing. He and co-authors have proposed that the progression of ageing can be treated as a problem in non-equilibrium thermodynamics and complex-systems dynamics. Fedichev and collaborators have published models describing how variability in health indicators increases with age and may predict lifespan limits. Subsequent studies extended this framework to distinguish between processes that might be reversible through intervention and those that appear thermodynamically irreversible. Nature gathered these developments in its 2024 “Gerophysics” article collection, co-edited by Fedichev and biologist Brian K. Kennedy, describing the field as an emerging interdisciplinary area linking statistical physics and biogerontology.

Gero

Gero.ai, co-founded in 2018 by Fedichev and Maxim Kholin in Singapore, develops physics-informed AI models trained on electronic medical records and molecular-level data to predict health trajectories and identify potential therapeutic targets for ageing-related conditions. In January 2023 Gero entered a research collaboration with Pfizer to identify therapeutic targets for fibrotic diseases. In July 2025 Gero signed a joint research and licence agreement with Chugai Pharmaceutical (a member of the Roche Group) to develop antibody therapies against targets identified by its AI models.

Selected publications

• Pyrkov T.V., Avchaciov K., Tarkhov A.E., Denisov K.A., & Fedichev P.O. (2021). “Longitudinal analysis of blood markers reveals progressive loss of resilience and predicts human lifespan limit.” Nature Communications, 12 (2765).
• Cortassa S., Fedichev P.O., et al. (2022). “Inhibitors of bacterial H₂S biogenesis targeting antibiotic resistance and tolerance.” Science.
• Tarkhov A.E., Denisov K.A., & Fedichev P.O. (2025). “Aging Clocks, Entropy, and the Challenge of Age Reversal.” Aging Biology.
• Fedichev P.O., Gruber J., Denisov K.A. (2024). “Discovery of Thermodynamic Control Variables that Independently Regulate Healthspan and Maximum Lifespan.” Aging Biology.

External links

• Official website
• Open Longevity – Debates